The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells

2012 ◽  
Vol 95 ◽  
pp. 195-200 ◽  
Author(s):  
Prachi Joshi ◽  
Soumyananda Chakraborti ◽  
Jaime E. Ramirez-Vick ◽  
Z.A. Ansari ◽  
Virendra Shanker ◽  
...  
2020 ◽  
Vol 9 ◽  
pp. 1812
Author(s):  
Solmaz Rahmani Barouji ◽  
Arman Shahabi ◽  
Mohammadali Torbati ◽  
Seyyed Mohammad Bagher Fazljou ◽  
Ahmad Yari Khosroushahi

Background: Mummy (Iranian pure shilajit) is a remedy with possessing anti-inflammatory, antioxidant and anticancer activities. This study aimed to examine mummy effects on epithelial-mesenchymal transition (EMT) and invasiveness of MCF-7 and MDA-MB-231 breast cancer (BC) cell lines with underlying its mechanism. Materials and Methods: The dose-dependent inhibitory effect of the mummy on cell proliferation in vitro was determined using the MTT assay.  Flow cytometry and 4’,6-diamidino-2-phenylindole dihydrochloride staining were respectively used for quantitative and qualitative analysis of cellular apoptosis, and gene expression analysis was conducted using real-time PCR. Results: MDA-MB-231 showed more sensitivity than the MCF-7 cell line to the anticancer activity of mummy, while mummy did not exhibit significant cell cytotoxicity against human normal cells (MCF-10A). The gene expression profile demonstrated a significant decrease in TGF-β1, TGF-βR1, TWIST1, NOTCH1, CTNNB1, SRC along with an increase in E-cadherin mRNA levels in mummy treated cells compared to the untreated control group (P≤0.05). Conclusion: Mummy triggers inhibition of EMT and metastasis in breast cancer cells mainly through the downregulation of TGFβ1 activity, and more studies required to find its specific anticancer activity with details. [GMJ.2020;9:e1812]


2020 ◽  
Vol 35 (1) ◽  
Author(s):  
Elumalai Kowsalya ◽  
Kithiyon MosaChristas ◽  
Chinna Rani Inbaraj Jaquline ◽  
Pannerselvam Balashanmugam ◽  
Thiyagarajan Devasena

RSC Advances ◽  
2015 ◽  
Vol 5 (112) ◽  
pp. 92596-92601 ◽  
Author(s):  
Abhijit Saha ◽  
Saswat Mohapatra ◽  
Prashant Kurkute ◽  
Batakrishna Jana ◽  
Jayita Sarkar ◽  
...  

A novel peptide docetaxel conjugate selectively kills NRP-1 overexpressing breast cancer cells, enhances anticancer activity of docetaxel without affecting the NRP-1 negative cells.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Somayeh Sadat Mehrnia ◽  
Bijan Hashemi ◽  
Seyed Javad Mowla ◽  
Maryam Nikkhah ◽  
Azim Arbabi

Abstract Background Gold nanoparticles (GNPs) have been used to sensitize cancer cells and enhance the absorbed dose delivered to such cells. Active targeting can provide specific effect and higher uptake of the GNPs in the tumor cells, while having small effect on healthy cells. The aim of this study was to assess the possible radiosensitiazation effect of GNPs conjugated with AS1411 aptamer (AS1411/GNPs) on cancer cells treated with 4 MeV electron beams. Materials and methods Cytotoxicity studies of the GNPs and AS1411/GNPs were carried out with MTT and MTS assay in different cancer cell lines of MCF-7, MDA-MB-231 and mammospheres of MCF-7 cells. Atomic absorption spectroscopy confirmed the cellular uptake of the gold particles. Radiosensitizing effect of the GNPs and AS1411/GNPs on the cancer cells was assessed by clonogenic assay. Result AS1411 aptamer increased the Au uptake in MCF-7 and MDA-MB-231 cells. Clonogenic survival data revealed that AS1411/GNPs at 12.5 mg/L could result in radiosensitization of the breast cancer cells and lead to a sensitizer enhancement ratio of 1.35 and 1.66 and 1.91 for MCf-7, MDA-MB-231 and mammosphere cells. Conclusion Gold nanoparticles delivery to the cancer cells was enhanced by AS1411 aptamer and led to enhanced radiation induced cancer cells death. The combination of our clonogenic assay and Au cell uptake results suggested that AS1411 aptamer has enhanced the radiation-induced cell death by increasing Au uptake. This enhanced sensitization contributed to cancer stem cell-like cells to 4 MeV electron beams. This is particularly important for future preclinical testing to open a new insight for the treatment of cancers.


Elkawnie ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. 48 ◽  
Author(s):  
Vivi Mardina ◽  
Tisna Harmawan ◽  
Halimatussakdiah Halimatussakdiah ◽  
Syafruddin Ilyas ◽  
Masitta Tanjung

Abstract : Sphagneticola trilobata (L.) J.F. Pruski is one of the perennial herbs that is widely used by the national and international community to treat various diseases including cancer. The objective of this study was to assessment the anticancer activity of n-hexane extract of S. trilobata leaves for inhibiting the growth of MCF-7 breast cancer cells in vitro by MTT (microculture tetrazolium salt) method. The n-hexane extract of sernai leaves was obtained from the maceration process of samples that were collected from the Langsa city, Aceh. The cytotoxicity test was carried out by incubating MCF-7 cells which had been exposed to several series of sample levels, viz. 1000; 500; 100; 50; 25; 10; 5 and 1 µg/mL. LC50 values are calculated using probit analysis. The results revealed that the n-hexane extract of S. trilobata leaves was cytotoxic against breast cancer cells (MCF-7) with an LC50 value of  0.037 μg /mL.Abstrak : Sphagneticola trilobata (L.) J.F. Pruski merupakan salah satu tanaman herbal yang digunakan secara luas oleh masyarakat nasional dan internasional untuk mengobati berbagai penyakit termasuk kanker. Penelitian ini bertujuan untuk mengetahui aktivitas antikanker ekstrak n-heksana daun S. trilobata dalam menghambat pertumbuhan sel kanker payudara MCF-7 secara in vitro dengan metode MTT (microculture tetrazolium salt). Ekstrak n-heksana daun sernai diperoleh dari proses maserasi sampel yang dikoleksi dari kota Langsa, Aceh. Uji sitotoksisitas dilakukan dengan menginkubasi sel MCF-7 yang telah dipaparkan beberapa seri  kadar sampel yaitu 1000, 500, 100, 50, 25, 10, 5 dan 1 µg/mL. Nilai LC50 dihitung dengan menggunakan analisa probit. Hasil penelitian menunjukkan bahwa ekstrak n-heksana daun S. trilobata bersifat sitotoksik terhadap sel kanker payudara (MCF-7) dengan harga LC50 sebesar 0,037 µg/mL. 


2021 ◽  
Author(s):  
Saeedeh Ahmadi ◽  
Iman Akbarzadeh ◽  
Mohsen Chiani ◽  
Mahmoud Seraj ◽  
Hassan Noorbazargan ◽  
...  

Abstract This study aimed to improve the anticancer activity of letrozole through a niosomal formulation. Optimized niosomal formulation of letrozole was achieved by response surface methodology (RSM). The niosomes were well-characterized by several methods. The anticancer activity and its mechanism were studied in MCF-7 and MDA-MB-231 breast cancer cells. The release of the drug from the niosomes was according to the Kors Meyer-Peppa kinetic model. The niosomes were stable with high encapsulation efficiency. Significant higher anticancer activity and more induction of apoptosis were obtained for niosomal letrozole. Results indicated that niosomes could be a promising drug carrier for delivery of letrozole to breast cancer cells.


Author(s):  
Branislava Janic ◽  
Fangchao Liu ◽  
Kevin R Bobbitt ◽  
Stephen L Brown ◽  
Indrin J Chetty ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document